Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX ‐622
Allergy · 2025-11 · 80 (11) · 3115-3126
DOI: 10.1111/all.16509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 20.02.2025. Verfasst von Michael B Murphy und 17 weiteren Autor:innen. Beteiligte Einrichtung: Celldex Therapeutics, Inc., Hampton, New Jersey, USA. Hauptthemen laut MEDLINE: Cytokines, Mast Cells, Antibodies, Bispecific. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Celldex Therapeutics.
Abstract (Originalsprache)
Background
Mast cells (MCs) respond to an array of allergens that drive allergic and inflammatory diseases. Stem cell factor (SCF), the ligand for the receptor KIT, is required for MC survival and function. Thymic stromal lymphopoietin (TSLP) is an alarmin that promotes Type 2 inflammation in asthma and other inflammatory diseases. We describe CDX‐622, a bispecific antibody (bsAb), that targets both SCF and TSLP to neutralize these distinct cytokines.
Methods
The bsAb CDX‐622 was developed from novel antagonist monoclonal antibodies (mAbs) to SCF (SCF‐12) and TSLP (1D10). CDX‐622 encodes the full‐length 1D10 mAb and the single‐chain variable fragment of SCF‐12, linked to the C‐terminus of the 1D10 heavy chain. CDX‐622 was modified to prevent Fcγ receptor interactions and enhance FcRn binding. CDX‐622 was tested using in vitro assays of MC and dendritic cell (DC) activation, an ex vivo human skin model, and in vivo studies in nonhuman primates.
Results
Novel SCF and TSLP mAbs with neutralizing activity were generated. The bsAb CDX‐622 potently inhibited SCF‐driven MC degranulation and TSLP‐mediated CCL17 release by DCs. In human skin samples treated with SCF and TSLP, CDX‐622 markedly reduced proinflammatory, MC, and DC‐related RNA signatures. Additionally, CDX‐622 and SCF‐12 mAb administered to cynomolgus macaques ( Macaca fascicularis ) had a profound effect on MCs without any observed toxicity.
Conclusions
CDX‐622 is a potent inhibitor of MCs through the neutralization of SCF and effectively blocks Type 2 inflammatory responses driven by TSLP. Dual inhibition of these cytokines may lead to improved clinical outcomes in certain inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Celldex Therapeutics, Inc., Hampton, New Jersey, USA.
ORCID-Profile: Michael B Murphy
Förderung
- Celldex Therapeutics
Zitieren
APA
Murphy, M. B., Vitale, L., O'Neill, T., Maurer, D. M., Malenchek, L., Crocker, A., Patterson, C., Mills-Chen, L., Saley, V., Antczak, N. M., Boyer, J. M., McManus, K. M., Montanari, N. R., Hammond, R. A., Goldstein, J., Thomas, L. J., Keler, T., & Alvarado, D. (2025). Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX ‐622. Allergy, 80(11), 3115-3126. https://doi.org/10.1111/all.16509
Vancouver
Murphy MB, Vitale L, O'Neill T, Maurer DM, Malenchek L, Crocker A, et al. Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX ‐622. Allergy. 2025;80(11):3115-3126. doi:10.1111/all.16509
BibTeX
@article{Murphy2025,
author = {Murphy, Michael B and Vitale, Laura and O'Neill, Thomas and Maurer, Deena M and Malenchek, Linda and Crocker, Andrea and Patterson, Colleen and Mills-Chen, Laura and Saley, Virginia and Antczak, Nicole M and Boyer, James M and McManus, Kelly M and Montanari, Noe Rico and Hammond, Russell A and Goldstein, Joel and Thomas, Lawrence J and Keler, Tibor and Alvarado, Diego},
title = {Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX ‐622},
journal = {Allergy},
year = {2025},
volume = {80},
number = {11},
pages = {3115--3126},
doi = {10.1111/all.16509}
}
EUVIMED